<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35089465</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-0646</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>40</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Investigational new drugs</Title>
          <ISOAbbreviation>Invest New Drugs</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.</ArticleTitle>
        <Pagination>
          <StartPage>506</StartPage>
          <EndPage>518</EndPage>
          <MedlinePgn>506-518</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10637-022-01218-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In cancer, myeloid-derived suppressor cells (MDSCs) are known to escape the host immune system by developing a highly suppressive environment. However, little is known about the molecular mechanism behind MDSC-mediated tumor cell evasion of the immune system. Toll-like receptor (TLR) signaling elicited in the tumor microenvironment has the potential to induce MDSC differentiations in different organs. Therefore, MDSC elimination by blocking the action of myeloid differentiation factor 88 (MyD88), which is a key adaptor-signaling molecule that affects TLR activity, seems to be an ideal tumor immunotherapy. Previous studies have proven that blocking MyD88 signaling with a novel MyD88 inhibitor (TJ-M2010-5, synthesized by Zhou's group) completely prevented colitis-associated colorectal cancer (CAC) development in mice.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In the present study, we investigated the impact of the novel MyD88 inhibitor on the number, phenotype, and function of MDSC in the mice model of CAC.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">We showed that CAC growth inhibition was involved in diminished MDSC generation, expansion, and suppressive function and that MDSC-mediated immune escape was dependent on MyD88 signaling pathway activation. MyD88 inhibitor treatment decreased the accumulation of CD11b<sup>+</sup>Gr1<sup>+</sup> MDSCs in mice with CAC, thereby reducing cytokine (GM-CSF, G-CSF, IL-1β, IL-6 and TGF-β) secretion associated with MDSC accumulation, and reducing the expression of molecules (iNOS, Arg-1 and IDO) associated with the suppressive capacity of MDSCs. In addition, MyD88 inhibitor treatment reduced the differentiation of MDSCs from myeloid cells and the suppressive capacity of MDSCs on the proliferation of activated CD4<sup>+</sup> T cells in vitro.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MDSCs are primary cellular targets of a novel MyD88 inhibitor during CAC development. Our findings prove that MyD88 signaling is involved in the regulation of the immunosuppressive functions of MDSCs. The novel MyD88 inhibitor TJ-M2010-5 is a new and effective agent that modulates MyD88 signaling to overcome MDSC suppressive functions, enabling the development of successful antitumor immunotherapy.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wang</LastName>
            <ForeName>Lu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Key Laboratory of Organ Transplantation, Ministry of Education, China; NHC Key Laboratory of Organ Transplantation, China; Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Hu</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Bin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Key Laboratory of Organ Transplantation, Ministry of Education, China; NHC Key Laboratory of Organ Transplantation, China; Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Lin</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-7058-0851</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Key Laboratory of Organ Transplantation, Ministry of Education, China; NHC Key Laboratory of Organ Transplantation, China; Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China. lxie@tjh.tjmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Invest New Drugs</MedlineTA>
        <NlmUniqueID>8309330</NlmUniqueID>
        <ISSNLinking>0167-6997</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000607343">5-(3-(4-(4-benzylpiperazin-1-yl)-N-(4-phenylthiazol-2-yl))propanamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C507780">Myd88 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053594">Myeloid Differentiation Factor 88</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000083023" MajorTopicYN="Y">Colitis-Associated Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053594" MajorTopicYN="Y">Myeloid Differentiation Factor 88</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072737" MajorTopicYN="Y">Myeloid-Derived Suppressor Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="Y">Piperazines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013844" MajorTopicYN="Y">Thiazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Colitis-associated colorectal cancer</Keyword>
        <Keyword MajorTopicYN="N">MyD88 inhibitor</Keyword>
        <Keyword MajorTopicYN="N">MyD88 signaling</Keyword>
        <Keyword MajorTopicYN="N">Myeloid-derived suppressor cells</Keyword>
      </KeywordList>
      <CoiStatement>Not applicable.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>12</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35089465</ArticleId>
        <ArticleId IdType="pmc">PMC9098617</ArticleId>
        <ArticleId IdType="doi">10.1007/s10637-022-01218-6</ArticleId>
        <ArticleId IdType="pii">10.1007/s10637-022-01218-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013;13:739–752. doi: 10.1038/nrc3581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3581</ArticleId>
            <ArticleId IdType="pmc">PMC4358792</ArticleId>
            <ArticleId IdType="pubmed">24060865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Can Res. 2012;72:3125–3130. doi: 10.1158/0008-5472.CAN-11-4094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-4094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH et al (2008) Next generation of immunotherapy for melanoma. J Clin Oncol: Official J Am Soc Clin Oncol 26:3445–55. 10.1200/JCO.2007.14.6423</Citation>
        </Reference>
        <Reference>
          <Citation>Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39:61–73. doi: 10.1016/j.immuni.2013.07.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2013.07.005</ArticleId>
            <ArticleId IdType="pmc">PMC3782392</ArticleId>
            <ArticleId IdType="pubmed">23890064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer immunology, immunotherapy : CII. 2012;61:255–263. doi: 10.1007/s00262-011-1161-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-011-1161-9</ArticleId>
            <ArticleId IdType="pubmed">22120756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–174. doi: 10.1038/nri2506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2506</ArticleId>
            <ArticleId IdType="pmc">PMC2828349</ArticleId>
            <ArticleId IdType="pubmed">19197294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer immunology, immunotherapy : CII. 2010;59:1593–1600. doi: 10.1007/s00262-010-0855-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-010-0855-8</ArticleId>
            <ArticleId IdType="pmc">PMC3706261</ArticleId>
            <ArticleId IdType="pubmed">20414655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khaled YS, Ammori BJ, Elkord E. Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol. 2013;91:493–502. doi: 10.1038/icb.2013.29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/icb.2013.29</ArticleId>
            <ArticleId IdType="pubmed">23797066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alizadeh D, Larmonier N. Chemotherapeutic targeting of cancer-induced immunosuppressive cells. Can Res. 2014;74:2663–2668. doi: 10.1158/0008-5472.CAN-14-0301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-14-0301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Umansky V, Sevko A. Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol. 2012;22:319–326. doi: 10.1016/j.semcancer.2012.02.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2012.02.003</ArticleId>
            <ArticleId IdType="pubmed">22349515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, et al.  Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol. 2010;40:22–35. doi: 10.1002/eji.200939903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.200939903</ArticleId>
            <ArticleId IdType="pubmed">19941314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, et al.  Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell. 2008;14:408–419. doi: 10.1016/j.ccr.2008.10.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2008.10.011</ArticleId>
            <ArticleId IdType="pmc">PMC2586894</ArticleId>
            <ArticleId IdType="pubmed">18977329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Can Res. 2007;67:10019–10026. doi: 10.1158/0008-5472.CAN-07-2354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-2354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Can Res. 2007;67:11438–11446. doi: 10.1158/0008-5472.CAN-07-1882.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-1882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takaku S, Terabe M, Ambrosino E, Peng J, Lonning S, McPherson JM, et al.  Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells. Int J Cancer. 2010;126:1666–1674. doi: 10.1002/ijc.24961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.24961</ArticleId>
            <ArticleId IdType="pmc">PMC2818422</ArticleId>
            <ArticleId IdType="pubmed">19830696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol. 2016;37:208–220. doi: 10.1016/j.it.2016.01.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2016.01.004</ArticleId>
            <ArticleId IdType="pmc">PMC4775398</ArticleId>
            <ArticleId IdType="pubmed">26858199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009;182:240–249. doi: 10.4049/jimmunol.182.1.240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.182.1.240</ArticleId>
            <ArticleId IdType="pubmed">19109155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007;179:977–983. doi: 10.4049/jimmunol.179.2.977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.179.2.977</ArticleId>
            <ArticleId IdType="pubmed">17617589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Egelston C, Kurko J, Besenyei T, Tryniszewska B, Rauch TA, Glant TT, et al.  Suppression of dendritic cell maturation and T cell proliferation by synovial fluid myeloid cells from mice with autoimmune arthritis. Arthritis Rheum. 2012;64:3179–3188. doi: 10.1002/art.34494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.34494</ArticleId>
            <ArticleId IdType="pmc">PMC3402579</ArticleId>
            <ArticleId IdType="pubmed">22492217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sumpter TL, Falo LD., Jr "Toll"-erance in the skin. Immunity. 2014;41:677–679. doi: 10.1016/j.immuni.2014.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2014.11.003</ArticleId>
            <ArticleId IdType="pubmed">25517608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skabytska Y, Wolbing F, Gunther C, Koberle M, Kaesler S, Chen KM, et al.  Cutaneous innate immune sensing of Toll-like receptor 2–6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. Immunity. 2014;41:762–775. doi: 10.1016/j.immuni.2014.10.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2014.10.009</ArticleId>
            <ArticleId IdType="pubmed">25456159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arora M, Poe SL, Oriss TB, Krishnamoorthy N, Yarlagadda M, Wenzel SE, et al.  TLR4/MyD88-induced CD11b+Gr-1 int F4/80+ non-migratory myeloid cells suppress Th2 effector function in the lung. Mucosal Immunol. 2010;3:578–593. doi: 10.1038/mi.2010.41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mi.2010.41</ArticleId>
            <ArticleId IdType="pmc">PMC2958091</ArticleId>
            <ArticleId IdType="pubmed">20664577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zoglmeier C, Bauer H, Noerenberg D, Wedekind G, Bittner P, Sandholzer N, et al.  CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;17:1765–1775. doi: 10.1158/1078-0432.CCR-10-2672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-10-2672</ArticleId>
            <ArticleId IdType="pubmed">21233400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siednienko J, Gajanayake T, Fitzgerald KA, Moynagh P, Miggin SM. Absence of MyD88 results in enhanced TLR3-dependent phosphorylation of IRF3 and increased IFN-beta and RANTES production. J Immunol. 2011;186:2514–2522. doi: 10.4049/jimmunol.1003093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1003093</ArticleId>
            <ArticleId IdType="pubmed">21248248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ray A, Chakraborty K, Ray P. Immunosuppressive MDSCs induced by TLR signaling during infection and role in resolution of inflammation. Front Cell Infect Microbiol. 2013;3:52. doi: 10.3389/fcimb.2013.00052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcimb.2013.00052</ArticleId>
            <ArticleId IdType="pmc">PMC3776133</ArticleId>
            <ArticleId IdType="pubmed">24066282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong EH, Chang SY, Lee BR, Kim YS, Lee JM, Kang CY, et al.  Blockade of Myd88 signaling induces antitumor effects by skewing the immunosuppressive function of myeloid-derived suppressor cells. Int J Cancer. 2013;132:2839–2848. doi: 10.1002/ijc.27974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.27974</ArticleId>
            <ArticleId IdType="pubmed">23184679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Zhang X, Wang H, Zhang M, Peng Y, Li M, et al.  Implication of myeloid differentiation factor 88 inhibitor TJ-M2010-5 for therapeutic intervention of hepatocellular carcinoma. Hepatology research : the official journal of the Japan Society of Hepatology. 2019;49:1182–1194. doi: 10.1111/hepr.13359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/hepr.13359</ArticleId>
            <ArticleId IdType="pubmed">31074165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding Z, Du D, Yang Y, Yang M, Miao Y, Zou Z, et al.  Short-term use of MyD88 inhibitor TJ-M2010-5 prevents d-galactosamine/lipopolysaccharide-induced acute liver injury in mice. Int Immunopharmacol. 2019;67:356–365. doi: 10.1016/j.intimp.2018.11.051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2018.11.051</ArticleId>
            <ArticleId IdType="pubmed">30583234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang M, Chen G, Zhang X, Ding Z, Miao Y, Yang Y, et al.  A novel MyD88 inhibitor attenuates allograft rejection after heterotopic tracheal transplantation in mice. Transpl Immunol. 2019;53:1–6. doi: 10.1016/j.trim.2018.11.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trim.2018.11.006</ArticleId>
            <ArticleId IdType="pubmed">30472390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li C, Zhang LM, Zhang X, Huang X, Liu Y, Li MQ, et al.  Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation. Transplantation. 2017;101:284–293. doi: 10.1097/TP.0000000000001471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/TP.0000000000001471</ArticleId>
            <ArticleId IdType="pubmed">27607533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xing S, Zhang X, Huang X, Xie L, Jiang F, Zhou P. Modulating the conformation of the TIR domain by a neoteric MyD88 inhibitor leads to the separation of GVHD from GVT. Leuk Lymphoma. 2019;60:1528–1539. doi: 10.1080/10428194.2018.1537487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10428194.2018.1537487</ArticleId>
            <ArticleId IdType="pubmed">30501537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miao Y, Ding Z, Zou Z, Yang Y, Yang M, Zhang X, et al.  Inhibition of MyD88 by a novel inhibitor reverses two-thirds of the infarct area in myocardial ischemia and reperfusion injury. American journal of translational research. 2020;12:5151–5169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7540094</ArticleId>
            <ArticleId IdType="pubmed">33042411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie L, Jiang FC, Zhang LM, He WT, Liu JH, Li MQ et al (2016) Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer. J Natl Cancer Inst 108.10.1093/jnci/djv364</Citation>
        </Reference>
        <Reference>
          <Citation>Condamine T, Mastio J, Gabrilovich DI. Transcriptional regulation of myeloid-derived suppressor cells. J Leukoc Biol. 2015;98:913–922. doi: 10.1189/jlb.4RI0515-204R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.4RI0515-204R</ArticleId>
            <ArticleId IdType="pmc">PMC4661041</ArticleId>
            <ArticleId IdType="pubmed">26337512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011;32:19–25. doi: 10.1016/j.it.2010.10.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2010.10.002</ArticleId>
            <ArticleId IdType="pmc">PMC3053028</ArticleId>
            <ArticleId IdType="pubmed">21067974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saleh M, Trinchieri G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol. 2011;11:9–20. doi: 10.1038/nri2891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2891</ArticleId>
            <ArticleId IdType="pubmed">21151034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berraondo P, Minute L, Ajona D, Corrales L, Melero I, Pio R. Innate immune mediators in cancer: between defense and resistance. Immunol Rev. 2016;274:290–306. doi: 10.1111/imr.12464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imr.12464</ArticleId>
            <ArticleId IdType="pubmed">27782320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Cicco P, Ercolano G, Ianaro A. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. Front Immunol. 2020;11:1680. doi: 10.3389/fimmu.2020.01680.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.01680</ArticleId>
            <ArticleId IdType="pmc">PMC7406792</ArticleId>
            <ArticleId IdType="pubmed">32849585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katoh H, Wang D, Daikoku T, Sun H, Dey SK, Dubois RN. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell. 2013;24:631–644. doi: 10.1016/j.ccr.2013.10.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2013.10.009</ArticleId>
            <ArticleId IdType="pmc">PMC3928012</ArticleId>
            <ArticleId IdType="pubmed">24229710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chun E, Lavoie S, Michaud M, Gallini CA, Kim J, Soucy G, et al.  CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function. Cell Rep. 2015;12:244–257. doi: 10.1016/j.celrep.2015.06.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2015.06.024</ArticleId>
            <ArticleId IdType="pmc">PMC4620029</ArticleId>
            <ArticleId IdType="pubmed">26146082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holmgaard RB, Zamarin D, Lesokhin A, Merghoub T, Wolchok JD. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine. 2016;6:50–58. doi: 10.1016/j.ebiom.2016.02.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ebiom.2016.02.024</ArticleId>
            <ArticleId IdType="pmc">PMC4856741</ArticleId>
            <ArticleId IdType="pubmed">27211548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao Y, Eissler N, Blanc KL, Johnsen JI, Kogner P, Kiessling R. Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016;22:3849–3859. doi: 10.1158/1078-0432.CCR-15-1912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-1912</ArticleId>
            <ArticleId IdType="pubmed">26957560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baert T, Vankerckhoven A, Riva M, Van Hoylandt A, Thirion G, Holger G, et al.  Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer. Front Immunol. 2019;10:1273. doi: 10.3389/fimmu.2019.01273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01273</ArticleId>
            <ArticleId IdType="pmc">PMC6558014</ArticleId>
            <ArticleId IdType="pubmed">31214202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Mitri D, Toso A, Alimonti A. Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21:3108–3112. doi: 10.1158/1078-0432.CCR-14-2261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-2261</ArticleId>
            <ArticleId IdType="pubmed">25967145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulsantiwong P, Pudla M, Srisaowakarn C, Boondit J, Utaisincharoen P. Pam2CSK4 and Pam3CSK4 induce iNOS expression via TBK1 and MyD88 molecules in mouse macrophage cell line RAW264.7. Inflammation research : official journal of the European Histamine Research Society [et al] 2017;66:843–853. doi: 10.1007/s00011-017-1063-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00011-017-1063-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu JT, Wu SX, Zhang H, Kuang F. Inhibition of MyD88 Signaling Skews Microglia/Macrophage Polarization and Attenuates Neuronal Apoptosis in the Hippocampus After Status Epilepticus in Mice. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2018;15:1093–1111. doi: 10.1007/s13311-018-0653-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-018-0653-0</ArticleId>
            <ArticleId IdType="pmc">PMC6277303</ArticleId>
            <ArticleId IdType="pubmed">30112701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu H, Zhang G, Huang J, Ma S, Mi K, Cheng J, et al.  Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-kappaB signaling in vitro. J Transl Med. 2016;14:104. doi: 10.1186/s12967-016-0845-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-016-0845-5</ArticleId>
            <ArticleId IdType="pmc">PMC4847224</ArticleId>
            <ArticleId IdType="pubmed">27118139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13:828–835. doi: 10.1038/nm1609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1609</ArticleId>
            <ArticleId IdType="pmc">PMC2135607</ArticleId>
            <ArticleId IdType="pubmed">17603493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schouppe E, Mommer C, Movahedi K, Laoui D, Morias Y, Gysemans C, et al.  Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events. Eur J Immunol. 2013;43:2930–2942. doi: 10.1002/eji.201343349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201343349</ArticleId>
            <ArticleId IdType="pubmed">23878002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valanparambil RM, Tam M, Jardim A, Geary TG, Stevenson MM. Primary Heligmosomoides polygyrus bakeri infection induces myeloid-derived suppressor cells that suppress CD4(+) Th2 responses and promote chronic infection. Mucosal Immunol. 2017;10:238–249. doi: 10.1038/mi.2016.36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mi.2016.36</ArticleId>
            <ArticleId IdType="pubmed">27072608</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35089465</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-0646</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>40</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Investigational new drugs</Title>
          <ISOAbbreviation>Invest New Drugs</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.</ArticleTitle>
        <Pagination>
          <StartPage>506</StartPage>
          <EndPage>518</EndPage>
          <MedlinePgn>506-518</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10637-022-01218-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In cancer, myeloid-derived suppressor cells (MDSCs) are known to escape the host immune system by developing a highly suppressive environment. However, little is known about the molecular mechanism behind MDSC-mediated tumor cell evasion of the immune system. Toll-like receptor (TLR) signaling elicited in the tumor microenvironment has the potential to induce MDSC differentiations in different organs. Therefore, MDSC elimination by blocking the action of myeloid differentiation factor 88 (MyD88), which is a key adaptor-signaling molecule that affects TLR activity, seems to be an ideal tumor immunotherapy. Previous studies have proven that blocking MyD88 signaling with a novel MyD88 inhibitor (TJ-M2010-5, synthesized by Zhou's group) completely prevented colitis-associated colorectal cancer (CAC) development in mice.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In the present study, we investigated the impact of the novel MyD88 inhibitor on the number, phenotype, and function of MDSC in the mice model of CAC.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">We showed that CAC growth inhibition was involved in diminished MDSC generation, expansion, and suppressive function and that MDSC-mediated immune escape was dependent on MyD88 signaling pathway activation. MyD88 inhibitor treatment decreased the accumulation of CD11b<sup>+</sup>Gr1<sup>+</sup> MDSCs in mice with CAC, thereby reducing cytokine (GM-CSF, G-CSF, IL-1β, IL-6 and TGF-β) secretion associated with MDSC accumulation, and reducing the expression of molecules (iNOS, Arg-1 and IDO) associated with the suppressive capacity of MDSCs. In addition, MyD88 inhibitor treatment reduced the differentiation of MDSCs from myeloid cells and the suppressive capacity of MDSCs on the proliferation of activated CD4<sup>+</sup> T cells in vitro.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MDSCs are primary cellular targets of a novel MyD88 inhibitor during CAC development. Our findings prove that MyD88 signaling is involved in the regulation of the immunosuppressive functions of MDSCs. The novel MyD88 inhibitor TJ-M2010-5 is a new and effective agent that modulates MyD88 signaling to overcome MDSC suppressive functions, enabling the development of successful antitumor immunotherapy.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wang</LastName>
            <ForeName>Lu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Key Laboratory of Organ Transplantation, Ministry of Education, China; NHC Key Laboratory of Organ Transplantation, China; Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Hu</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Bin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Key Laboratory of Organ Transplantation, Ministry of Education, China; NHC Key Laboratory of Organ Transplantation, China; Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Lin</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-7058-0851</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Key Laboratory of Organ Transplantation, Ministry of Education, China; NHC Key Laboratory of Organ Transplantation, China; Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China. lxie@tjh.tjmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Invest New Drugs</MedlineTA>
        <NlmUniqueID>8309330</NlmUniqueID>
        <ISSNLinking>0167-6997</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000607343">5-(3-(4-(4-benzylpiperazin-1-yl)-N-(4-phenylthiazol-2-yl))propanamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C507780">Myd88 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053594">Myeloid Differentiation Factor 88</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000083023" MajorTopicYN="Y">Colitis-Associated Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053594" MajorTopicYN="Y">Myeloid Differentiation Factor 88</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072737" MajorTopicYN="Y">Myeloid-Derived Suppressor Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="Y">Piperazines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013844" MajorTopicYN="Y">Thiazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Colitis-associated colorectal cancer</Keyword>
        <Keyword MajorTopicYN="N">MyD88 inhibitor</Keyword>
        <Keyword MajorTopicYN="N">MyD88 signaling</Keyword>
        <Keyword MajorTopicYN="N">Myeloid-derived suppressor cells</Keyword>
      </KeywordList>
      <CoiStatement>Not applicable.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>12</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35089465</ArticleId>
        <ArticleId IdType="pmc">PMC9098617</ArticleId>
        <ArticleId IdType="doi">10.1007/s10637-022-01218-6</ArticleId>
        <ArticleId IdType="pii">10.1007/s10637-022-01218-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013;13:739–752. doi: 10.1038/nrc3581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3581</ArticleId>
            <ArticleId IdType="pmc">PMC4358792</ArticleId>
            <ArticleId IdType="pubmed">24060865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Can Res. 2012;72:3125–3130. doi: 10.1158/0008-5472.CAN-11-4094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-4094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH et al (2008) Next generation of immunotherapy for melanoma. J Clin Oncol: Official J Am Soc Clin Oncol 26:3445–55. 10.1200/JCO.2007.14.6423</Citation>
        </Reference>
        <Reference>
          <Citation>Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39:61–73. doi: 10.1016/j.immuni.2013.07.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2013.07.005</ArticleId>
            <ArticleId IdType="pmc">PMC3782392</ArticleId>
            <ArticleId IdType="pubmed">23890064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer immunology, immunotherapy : CII. 2012;61:255–263. doi: 10.1007/s00262-011-1161-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-011-1161-9</ArticleId>
            <ArticleId IdType="pubmed">22120756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–174. doi: 10.1038/nri2506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2506</ArticleId>
            <ArticleId IdType="pmc">PMC2828349</ArticleId>
            <ArticleId IdType="pubmed">19197294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer immunology, immunotherapy : CII. 2010;59:1593–1600. doi: 10.1007/s00262-010-0855-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-010-0855-8</ArticleId>
            <ArticleId IdType="pmc">PMC3706261</ArticleId>
            <ArticleId IdType="pubmed">20414655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khaled YS, Ammori BJ, Elkord E. Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol. 2013;91:493–502. doi: 10.1038/icb.2013.29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/icb.2013.29</ArticleId>
            <ArticleId IdType="pubmed">23797066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alizadeh D, Larmonier N. Chemotherapeutic targeting of cancer-induced immunosuppressive cells. Can Res. 2014;74:2663–2668. doi: 10.1158/0008-5472.CAN-14-0301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-14-0301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Umansky V, Sevko A. Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol. 2012;22:319–326. doi: 10.1016/j.semcancer.2012.02.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2012.02.003</ArticleId>
            <ArticleId IdType="pubmed">22349515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, et al.  Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol. 2010;40:22–35. doi: 10.1002/eji.200939903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.200939903</ArticleId>
            <ArticleId IdType="pubmed">19941314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, et al.  Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell. 2008;14:408–419. doi: 10.1016/j.ccr.2008.10.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2008.10.011</ArticleId>
            <ArticleId IdType="pmc">PMC2586894</ArticleId>
            <ArticleId IdType="pubmed">18977329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Can Res. 2007;67:10019–10026. doi: 10.1158/0008-5472.CAN-07-2354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-2354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Can Res. 2007;67:11438–11446. doi: 10.1158/0008-5472.CAN-07-1882.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-1882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takaku S, Terabe M, Ambrosino E, Peng J, Lonning S, McPherson JM, et al.  Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells. Int J Cancer. 2010;126:1666–1674. doi: 10.1002/ijc.24961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.24961</ArticleId>
            <ArticleId IdType="pmc">PMC2818422</ArticleId>
            <ArticleId IdType="pubmed">19830696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol. 2016;37:208–220. doi: 10.1016/j.it.2016.01.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2016.01.004</ArticleId>
            <ArticleId IdType="pmc">PMC4775398</ArticleId>
            <ArticleId IdType="pubmed">26858199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009;182:240–249. doi: 10.4049/jimmunol.182.1.240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.182.1.240</ArticleId>
            <ArticleId IdType="pubmed">19109155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007;179:977–983. doi: 10.4049/jimmunol.179.2.977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.179.2.977</ArticleId>
            <ArticleId IdType="pubmed">17617589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Egelston C, Kurko J, Besenyei T, Tryniszewska B, Rauch TA, Glant TT, et al.  Suppression of dendritic cell maturation and T cell proliferation by synovial fluid myeloid cells from mice with autoimmune arthritis. Arthritis Rheum. 2012;64:3179–3188. doi: 10.1002/art.34494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.34494</ArticleId>
            <ArticleId IdType="pmc">PMC3402579</ArticleId>
            <ArticleId IdType="pubmed">22492217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sumpter TL, Falo LD., Jr "Toll"-erance in the skin. Immunity. 2014;41:677–679. doi: 10.1016/j.immuni.2014.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2014.11.003</ArticleId>
            <ArticleId IdType="pubmed">25517608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skabytska Y, Wolbing F, Gunther C, Koberle M, Kaesler S, Chen KM, et al.  Cutaneous innate immune sensing of Toll-like receptor 2–6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. Immunity. 2014;41:762–775. doi: 10.1016/j.immuni.2014.10.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2014.10.009</ArticleId>
            <ArticleId IdType="pubmed">25456159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arora M, Poe SL, Oriss TB, Krishnamoorthy N, Yarlagadda M, Wenzel SE, et al.  TLR4/MyD88-induced CD11b+Gr-1 int F4/80+ non-migratory myeloid cells suppress Th2 effector function in the lung. Mucosal Immunol. 2010;3:578–593. doi: 10.1038/mi.2010.41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mi.2010.41</ArticleId>
            <ArticleId IdType="pmc">PMC2958091</ArticleId>
            <ArticleId IdType="pubmed">20664577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zoglmeier C, Bauer H, Noerenberg D, Wedekind G, Bittner P, Sandholzer N, et al.  CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;17:1765–1775. doi: 10.1158/1078-0432.CCR-10-2672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-10-2672</ArticleId>
            <ArticleId IdType="pubmed">21233400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siednienko J, Gajanayake T, Fitzgerald KA, Moynagh P, Miggin SM. Absence of MyD88 results in enhanced TLR3-dependent phosphorylation of IRF3 and increased IFN-beta and RANTES production. J Immunol. 2011;186:2514–2522. doi: 10.4049/jimmunol.1003093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1003093</ArticleId>
            <ArticleId IdType="pubmed">21248248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ray A, Chakraborty K, Ray P. Immunosuppressive MDSCs induced by TLR signaling during infection and role in resolution of inflammation. Front Cell Infect Microbiol. 2013;3:52. doi: 10.3389/fcimb.2013.00052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcimb.2013.00052</ArticleId>
            <ArticleId IdType="pmc">PMC3776133</ArticleId>
            <ArticleId IdType="pubmed">24066282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong EH, Chang SY, Lee BR, Kim YS, Lee JM, Kang CY, et al.  Blockade of Myd88 signaling induces antitumor effects by skewing the immunosuppressive function of myeloid-derived suppressor cells. Int J Cancer. 2013;132:2839–2848. doi: 10.1002/ijc.27974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.27974</ArticleId>
            <ArticleId IdType="pubmed">23184679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Zhang X, Wang H, Zhang M, Peng Y, Li M, et al.  Implication of myeloid differentiation factor 88 inhibitor TJ-M2010-5 for therapeutic intervention of hepatocellular carcinoma. Hepatology research : the official journal of the Japan Society of Hepatology. 2019;49:1182–1194. doi: 10.1111/hepr.13359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/hepr.13359</ArticleId>
            <ArticleId IdType="pubmed">31074165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding Z, Du D, Yang Y, Yang M, Miao Y, Zou Z, et al.  Short-term use of MyD88 inhibitor TJ-M2010-5 prevents d-galactosamine/lipopolysaccharide-induced acute liver injury in mice. Int Immunopharmacol. 2019;67:356–365. doi: 10.1016/j.intimp.2018.11.051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2018.11.051</ArticleId>
            <ArticleId IdType="pubmed">30583234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang M, Chen G, Zhang X, Ding Z, Miao Y, Yang Y, et al.  A novel MyD88 inhibitor attenuates allograft rejection after heterotopic tracheal transplantation in mice. Transpl Immunol. 2019;53:1–6. doi: 10.1016/j.trim.2018.11.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trim.2018.11.006</ArticleId>
            <ArticleId IdType="pubmed">30472390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li C, Zhang LM, Zhang X, Huang X, Liu Y, Li MQ, et al.  Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation. Transplantation. 2017;101:284–293. doi: 10.1097/TP.0000000000001471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/TP.0000000000001471</ArticleId>
            <ArticleId IdType="pubmed">27607533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xing S, Zhang X, Huang X, Xie L, Jiang F, Zhou P. Modulating the conformation of the TIR domain by a neoteric MyD88 inhibitor leads to the separation of GVHD from GVT. Leuk Lymphoma. 2019;60:1528–1539. doi: 10.1080/10428194.2018.1537487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10428194.2018.1537487</ArticleId>
            <ArticleId IdType="pubmed">30501537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miao Y, Ding Z, Zou Z, Yang Y, Yang M, Zhang X, et al.  Inhibition of MyD88 by a novel inhibitor reverses two-thirds of the infarct area in myocardial ischemia and reperfusion injury. American journal of translational research. 2020;12:5151–5169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7540094</ArticleId>
            <ArticleId IdType="pubmed">33042411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie L, Jiang FC, Zhang LM, He WT, Liu JH, Li MQ et al (2016) Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer. J Natl Cancer Inst 108.10.1093/jnci/djv364</Citation>
        </Reference>
        <Reference>
          <Citation>Condamine T, Mastio J, Gabrilovich DI. Transcriptional regulation of myeloid-derived suppressor cells. J Leukoc Biol. 2015;98:913–922. doi: 10.1189/jlb.4RI0515-204R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.4RI0515-204R</ArticleId>
            <ArticleId IdType="pmc">PMC4661041</ArticleId>
            <ArticleId IdType="pubmed">26337512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011;32:19–25. doi: 10.1016/j.it.2010.10.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2010.10.002</ArticleId>
            <ArticleId IdType="pmc">PMC3053028</ArticleId>
            <ArticleId IdType="pubmed">21067974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saleh M, Trinchieri G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol. 2011;11:9–20. doi: 10.1038/nri2891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2891</ArticleId>
            <ArticleId IdType="pubmed">21151034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berraondo P, Minute L, Ajona D, Corrales L, Melero I, Pio R. Innate immune mediators in cancer: between defense and resistance. Immunol Rev. 2016;274:290–306. doi: 10.1111/imr.12464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imr.12464</ArticleId>
            <ArticleId IdType="pubmed">27782320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Cicco P, Ercolano G, Ianaro A. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. Front Immunol. 2020;11:1680. doi: 10.3389/fimmu.2020.01680.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.01680</ArticleId>
            <ArticleId IdType="pmc">PMC7406792</ArticleId>
            <ArticleId IdType="pubmed">32849585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katoh H, Wang D, Daikoku T, Sun H, Dey SK, Dubois RN. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell. 2013;24:631–644. doi: 10.1016/j.ccr.2013.10.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2013.10.009</ArticleId>
            <ArticleId IdType="pmc">PMC3928012</ArticleId>
            <ArticleId IdType="pubmed">24229710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chun E, Lavoie S, Michaud M, Gallini CA, Kim J, Soucy G, et al.  CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function. Cell Rep. 2015;12:244–257. doi: 10.1016/j.celrep.2015.06.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2015.06.024</ArticleId>
            <ArticleId IdType="pmc">PMC4620029</ArticleId>
            <ArticleId IdType="pubmed">26146082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holmgaard RB, Zamarin D, Lesokhin A, Merghoub T, Wolchok JD. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine. 2016;6:50–58. doi: 10.1016/j.ebiom.2016.02.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ebiom.2016.02.024</ArticleId>
            <ArticleId IdType="pmc">PMC4856741</ArticleId>
            <ArticleId IdType="pubmed">27211548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao Y, Eissler N, Blanc KL, Johnsen JI, Kogner P, Kiessling R. Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016;22:3849–3859. doi: 10.1158/1078-0432.CCR-15-1912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-1912</ArticleId>
            <ArticleId IdType="pubmed">26957560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baert T, Vankerckhoven A, Riva M, Van Hoylandt A, Thirion G, Holger G, et al.  Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer. Front Immunol. 2019;10:1273. doi: 10.3389/fimmu.2019.01273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01273</ArticleId>
            <ArticleId IdType="pmc">PMC6558014</ArticleId>
            <ArticleId IdType="pubmed">31214202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Mitri D, Toso A, Alimonti A. Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21:3108–3112. doi: 10.1158/1078-0432.CCR-14-2261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-2261</ArticleId>
            <ArticleId IdType="pubmed">25967145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulsantiwong P, Pudla M, Srisaowakarn C, Boondit J, Utaisincharoen P. Pam2CSK4 and Pam3CSK4 induce iNOS expression via TBK1 and MyD88 molecules in mouse macrophage cell line RAW264.7. Inflammation research : official journal of the European Histamine Research Society [et al] 2017;66:843–853. doi: 10.1007/s00011-017-1063-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00011-017-1063-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu JT, Wu SX, Zhang H, Kuang F. Inhibition of MyD88 Signaling Skews Microglia/Macrophage Polarization and Attenuates Neuronal Apoptosis in the Hippocampus After Status Epilepticus in Mice. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2018;15:1093–1111. doi: 10.1007/s13311-018-0653-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-018-0653-0</ArticleId>
            <ArticleId IdType="pmc">PMC6277303</ArticleId>
            <ArticleId IdType="pubmed">30112701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu H, Zhang G, Huang J, Ma S, Mi K, Cheng J, et al.  Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-kappaB signaling in vitro. J Transl Med. 2016;14:104. doi: 10.1186/s12967-016-0845-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-016-0845-5</ArticleId>
            <ArticleId IdType="pmc">PMC4847224</ArticleId>
            <ArticleId IdType="pubmed">27118139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13:828–835. doi: 10.1038/nm1609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1609</ArticleId>
            <ArticleId IdType="pmc">PMC2135607</ArticleId>
            <ArticleId IdType="pubmed">17603493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schouppe E, Mommer C, Movahedi K, Laoui D, Morias Y, Gysemans C, et al.  Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events. Eur J Immunol. 2013;43:2930–2942. doi: 10.1002/eji.201343349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201343349</ArticleId>
            <ArticleId IdType="pubmed">23878002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valanparambil RM, Tam M, Jardim A, Geary TG, Stevenson MM. Primary Heligmosomoides polygyrus bakeri infection induces myeloid-derived suppressor cells that suppress CD4(+) Th2 responses and promote chronic infection. Mucosal Immunol. 2017;10:238–249. doi: 10.1038/mi.2016.36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mi.2016.36</ArticleId>
            <ArticleId IdType="pubmed">27072608</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
